Deepcell, a Menlo Park, CA-based life science company pioneering AI-powered single cell classification and isolation for basic and translational research, closed its $73m Series B financing.
This round, which brings Deepcell’s overall funding to nearly $100 million since it was founded in 2017, was led by Koch Disruptive Technologies and joined by new investors including Bridger Healthcare, Horizons Ventures, Casdin Capital and lead investors from previous rounds, Andreessen Horowitz and Bow Capital as well as Jeff Dean, Head of Google Brain, and Matt Mcllwain, Managing Director at Madrona Venture Group. David Mauney, Managing Director at KDT, joined the Board of Deepcell. In addition to David Mauney, Blake Goodner and Matt Posard will join Deepcell’s Board of Directors. Mr. Goodner is a founding member of Bridger Management and Advisory Board Member with The Duke-Margolis Center for Health Policy, and Mr. Posard is a 30-year life sciences industry veteran and former Senior Vice President of Emerging Markets at Illumina.
The company intends to use the funds to continue product development and enable early commercial introduction of a new standard for obtaining biological insights from single cell analysis.
Led by Maddison Masaeli, CEO and Co-founder, and Mahyar Salek, President, CTO and co-founder, Deepcell provides a platform that combines advances in AI, proprietary microfluidics, high resolution optics, and a growing cell atlas with over 1 billion images to analyze and sort cells based on visual features. This allows researchers to characterize and gain new insights from single cells at levels of resolution previously unseen with other “omics” based tools.
FinSMEs
17/03/2022